Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibito...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/4/1973 |
| _version_ | 1797298092047859712 |
|---|---|
| author | Khine S. Shan Amalia Bonano-Rios Nyein Wint Yee Theik Atif Hussein Marcelo Blaya |
| author_facet | Khine S. Shan Amalia Bonano-Rios Nyein Wint Yee Theik Atif Hussein Marcelo Blaya |
| author_sort | Khine S. Shan |
| collection | DOAJ |
| description | The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibitors by the Food and Drug Administration (FDA) over the past decade. However, the limited clinical efficacy of these inhibitors, intolerable toxicities, and acquired resistances limit the clinical application of PI3K inhibitors. This review discusses the PI3K signaling pathway, alterations in the PI3K pathway causing carcinogenesis, current and novel PI3K pathway inhibitors, adverse effects, resistance mechanisms, challenging issues, and future directions of PI3K pathway inhibitors. |
| first_indexed | 2024-03-07T22:29:52Z |
| format | Article |
| id | doaj.art-98a59503699a411db4055808e3ec768b |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-07T22:29:52Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-98a59503699a411db4055808e3ec768b2024-02-23T15:19:15ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-02-01254197310.3390/ijms25041973Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various CancersKhine S. Shan0Amalia Bonano-Rios1Nyein Wint Yee Theik2Atif Hussein3Marcelo Blaya4Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USADivision of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USADivision of Internal Medicine, Memorial Health Care, Pembroke Pines, FL 33028, USADivision of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USADivision of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USAThe dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibitors by the Food and Drug Administration (FDA) over the past decade. However, the limited clinical efficacy of these inhibitors, intolerable toxicities, and acquired resistances limit the clinical application of PI3K inhibitors. This review discusses the PI3K signaling pathway, alterations in the PI3K pathway causing carcinogenesis, current and novel PI3K pathway inhibitors, adverse effects, resistance mechanisms, challenging issues, and future directions of PI3K pathway inhibitors.https://www.mdpi.com/1422-0067/25/4/1973phosphatidylinositol-3-kinasePI3KAKTmTORtargeted therapymolecular profiling |
| spellingShingle | Khine S. Shan Amalia Bonano-Rios Nyein Wint Yee Theik Atif Hussein Marcelo Blaya Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers International Journal of Molecular Sciences phosphatidylinositol-3-kinase PI3K AKT mTOR targeted therapy molecular profiling |
| title | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers |
| title_full | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers |
| title_fullStr | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers |
| title_full_unstemmed | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers |
| title_short | Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers |
| title_sort | molecular targeting of the phosphoinositide 3 protein kinase pi3k pathway across various cancers |
| topic | phosphatidylinositol-3-kinase PI3K AKT mTOR targeted therapy molecular profiling |
| url | https://www.mdpi.com/1422-0067/25/4/1973 |
| work_keys_str_mv | AT khinesshan moleculartargetingofthephosphoinositide3proteinkinasepi3kpathwayacrossvariouscancers AT amaliabonanorios moleculartargetingofthephosphoinositide3proteinkinasepi3kpathwayacrossvariouscancers AT nyeinwintyeetheik moleculartargetingofthephosphoinositide3proteinkinasepi3kpathwayacrossvariouscancers AT atifhussein moleculartargetingofthephosphoinositide3proteinkinasepi3kpathwayacrossvariouscancers AT marceloblaya moleculartargetingofthephosphoinositide3proteinkinasepi3kpathwayacrossvariouscancers |